NeoGenomics (NEO) Expected to Announce Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of $0.0060 per share and revenue of $184.53 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 4:30 PM ET.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $190.17 million during the quarter, compared to the consensus estimate of $188.25 million. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.04 EPS. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Price Performance

NEO stock opened at $8.29 on Friday. The company has a fifty day moving average price of $8.61 and a 200-day moving average price of $10.44. The company has a market capitalization of $1.08 billion, a P/E ratio of -9.87 and a beta of 1.72. NeoGenomics has a 52-week low of $4.72 and a 52-week high of $13.74. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.94 and a current ratio of 4.26.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. William Blair reaffirmed a “market perform” rating on shares of NeoGenomics in a research note on Monday, March 16th. Piper Sandler raised their price target on shares of NeoGenomics from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Monday, March 16th. Zacks Research downgraded shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a research note on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $11.86.

Institutional Investors Weigh In On NeoGenomics

Large investors have recently modified their holdings of the company. Loomis Sayles & Co. L P acquired a new stake in NeoGenomics in the fourth quarter worth $19,182,000. American Capital Management Inc. grew its holdings in NeoGenomics by 120.9% in the third quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock worth $18,105,000 after purchasing an additional 1,283,390 shares during the period. T. Rowe Price Investment Management Inc. grew its holdings in NeoGenomics by 69.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,218,727 shares of the medical research company’s stock worth $26,093,000 after purchasing an additional 912,788 shares during the period. Trexquant Investment LP acquired a new stake in NeoGenomics in the fourth quarter worth $10,414,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in NeoGenomics in the second quarter worth $6,071,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.